Journal of Pharmacy and Pharmacology 2006-07-01

Enhancement of availability of cloricromene at brain level by a lipophilic prodrug.

R Pignatello, A Maltese, F Maugeri, C Bucolo

Index: J. Pharm. Pharmacol. 58(7) , 1001-5, (2006)

Full Text: HTML

Abstract

The pharmacokinetics of a lipophilic alkylamino acid (LAA) prodrug of cloricromene (AD6), name CLOR-C4, was studied in rat plasma and brain. In particular, we observed that the intraperitoneal administration of CLOR-C4 to rats was able to provide a slight but statistically significant higher concentration of the active drug metabolite (cloricromene acid) in the brain compared with the parent drug administered by the same way. The correlation between pharmacokinetic data and calculated partition (LogP) and brain distribution coefficients (LogBB) supported the hypothesis that the amphiphilic nature of the LAA promoiety could be responsible for a better penetration into the brain, more than the simple increase of lipophilicity gained with respect to the parent drug.

Related Compounds

  • Cloricromenehydroc...

Related Articles:

Cloricromene in endotoxemia: role of NF-kappaB.

2004-08-01

[Naunyn Schmiedebergs Arch. Pharmacol. 370(2) , 140-5, (2004)]

Tumor necrosis factor induces E-selectin production in splanchnic artery occlusion shock.

1995-04-01

[Am. J. Physiol. 268(4 Pt 2) , H1412-7, (1995)]

Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.

2006-01-01

[AAPS PharmSciTech 7(1) , E27, (2006)]

Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.

2006-04-01

[Naunyn Schmiedebergs Arch. Pharmacol. 373(1) , 51-9, (2006)]

Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopathy Multicenter Prospective Study.

2000-01-01

[Vasc. Med. 5(2) , 83-9, (2000)]

More Articles...